Keating Investment Counselors Inc. continued to hold its stake in shares of AbbVie Inc. (NYSE:ABBV) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 6,575 shares of the company’s stock at the end of the second quarter. Keating Investment Counselors Inc.’s holdings in AbbVie were worth $477,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. WealthTrust Axiom LLC grew its holdings in AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after acquiring an additional 15 shares during the period. Abner Herrman & Brock LLC grew its holdings in AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after acquiring an additional 18 shares during the period. Bollard Group LLC grew its holdings in AbbVie by 0.5% during the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after acquiring an additional 19 shares during the period. St. Louis Trust Co grew its holdings in AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after purchasing an additional 23 shares during the period. Finally, TRUE Private Wealth Advisors grew its holdings in AbbVie by 0.6% in the second quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock valued at $349,000 after purchasing an additional 27 shares during the period. Hedge funds and other institutional investors own 69.32% of the company’s stock.
In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the sale, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the sale, the vice president now directly owns 10,007 shares in the company, valued at $880,616. The disclosure for this sale can be found here. Insiders sold 277,125 shares of company stock worth $25,891,756 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.
Shares of AbbVie Inc. (ABBV) opened at $94.40 on Thursday. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The stock has a market capitalization of $152,315.39, a P/E ratio of 17.97, a PEG ratio of 1.35 and a beta of 1.52. AbbVie Inc. has a 12 month low of $58.80 and a 12 month high of $98.52.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 earnings per share. research analysts predict that AbbVie Inc. will post 5.55 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.01%. AbbVie’s payout ratio is currently 62.29%.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.